Extended Data Fig. 3: ROC Analyses examining FGF21 as a Diagnostic Biomarker for Mitochondrial Disease. | Nature Metabolism

Extended Data Fig. 3: ROC Analyses examining FGF21 as a Diagnostic Biomarker for Mitochondrial Disease.

From: Mitochondrial and psychosocial stress-related regulation of FGF21 in humans

Extended Data Fig. 3

Receiver operating characteristic (ROC) curve analyses for the prediction of mitochondrial disease based on the serum levels of FGF21 measured by enzyme-linked immunosorbent assay. Plots depict percentage sensitivity plotted against percentage specificity to assess diagnostic performance of serum FGF21 in distinguishing MitoD from healthy participants. (a) Two curves comparing the diagnostic performance of fasting (AM) versus fed (PM) measures of serum FGF21, showing that fed (PM) FGF21 shows enhanced performance with AUC = 0.86. (b) Two plots comparing the diagnostic performance of fed and fasting FGF21 for Deletion and Mutation (m.3243A>G + MELAS) groups separately, alongside a groups-combined curve. Curves demonstrate highest discriminative ability for the Deletion group in the fed state (AUC = 0.98). (c) Comparison of FGF21 and GDF15 diagnostic performance in the fed state and (d) the performance of FGF21 and GDF15 combined. The combined curve was generated using individual FGF21 and GDF15 measures and calculating predicted probabilities by logistic regression for each participant measurement at PM-fed time point.

Source data

Back to article page